Image may be NSFW.
Clik here to view.
Clik here to view.
Stifel starts MEI Pharma at buy
Stifel Nicolaus has initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and $11 target price. The stock closed at $7.95 on Monday. “We view MEI’s lead clinical candidate Pracinostat as...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Roth adds MEI Pharma to Focus List, ups price target to $22
Roth Capital Partners has added “buy-rated” MEI Pharma (NASDAQ:MEIP) to its Focus List and raised its price target to $22 from $20. The stock closed at $7.68 on Wednesday. Analyst Joseph Pantginis...
View Article
More Pages to Explore .....
